North America Intragastric Balloon Market 2019-2028

MARKET OUTLOOK

The publisher, in its report on the North American intragastric balloon market, depicts that the industry is expected to flourish at a CAGR of 12.48% over the estimated period 2019-2028.
The United States and Canada together constitute the North American intragastric balloon market.

The intragastric balloon market in the United States is growing, due to the ever-increasing obesity rates, coupled with government funds towards research activities, undertaken by the market players regarding surgeries for treating obesity. It is reported that in 2018, about 39.8% of adults were obese in the country. Consequently, there is an upsurge in the number of bariatric surgeries performed every year. The intragastric ballooning procedure has proven to be effective in obesity treatment. Hence, the increasing adoption of these treatment options is estimated to push the growth of the intragastric balloon market in the United States.

In Canada, every fourth adult has clinical obesity, which means approximately 6 million Canadians may require support in controlling their body weight. Obesity is a major cause of type 2 diabetes, heart disease, high blood pressure, arthritis, stroke and cancer. The intragastric balloon is designed to be inserted into the stomach to restrict the amount of food the patient can eat. This is expected to increase the use of intragastric balloon in the treatment of obesity, which is aiding market growth in Canada.

COMPETITIVE OUTLOOK

Some major companies in the intragastric balloon market are Apollo Endosurgery Inc, ReShape Lifesciences Inc, Helioscopie, Districlass Medical, Obalon Therapeutics, MedSil and BAROnova.